Heparin-Free DALI LDL-Apheresis in Hyperlipidemic Patients: Efficacy, Safety and Biocompatibility
暂无分享,去创建一个
W. Samtleben | T. Bosch | A. Lennertz | C. Duhr | T. Wendler | O. Heinemann
[1] M. Toepfer,et al. DALI apheresis in hyperlipidemic patients: biocompatibility, efficacy, and selectivity of direct adsorption of lipoproteins from whole blood. , 2000, Artificial organs.
[2] W. Samtleben,et al. Low density lipoprotein hemoperfusion by direct adsorption of lipoproteins from whole blood (DALI apheresis): clinical experience from a single center. , 1999, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.
[3] Schaper,et al. DALI—the first human whole‐blood low‐density lipoprotein and lipoprotein (a) apheresis system in clinical use: procedure and clinical results , 1998, European journal of clinical investigation.
[4] W. Kleophas,et al. LDL hemoperfusion--a new procedure for LDL apheresis: first clinical application of an LDL adsorber compatible with human whole blood. , 2008, Artificial organs.
[5] A. Gotto,et al. Effects of lipid lowering therapy on progression of coronary and carotid artery disease. , 1997, Current Opinion in Lipidology.
[6] B. Gordon,et al. Current status of low density lipoprotein-apheresis for the therapy of severe hyperlipidemia , 1996, Current Opinion in Lipidology.
[7] T. Bosch. Lipid apheresis: from a heroic treatment to routine clinical practice. , 1996, Artificial organs.
[8] T. Lindhout. Biocompatibility of extracorporeal blood treatment. Selection of haemostatic parameters. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[9] M. Blumenstein,et al. Lipid apheresis by hemoperfusion: in vitro efficacy and ex vivo biocompatibility of a new low-density lipoprotein adsorber compatible with human whole blood. , 2008, Artificial organs.
[10] A. Yamamoto,et al. Assessment of the biocompatibility and long-term effect of LDL-apheresis by dextran sulfate-cellulose column. , 2008, Artificial organs.
[11] K. Bhoola,et al. Bioregulation of kinins: kallikreins, kininogens, and kininases. , 1992, Pharmacological reviews.
[12] J. Hirsh. Drug therapy : heparin , 1991 .
[13] J. Nordenström,et al. Lipolytic and anticoagulant activities of a low molecular weight fragment of heparin , 1985, European journal of clinical investigation.
[14] S. Hosoda,et al. An improved method for the determination of human blood kinin levels by sensitive kinin radioimmunoassay. , 1982, Endocrinologia japonica.
[15] M. Kazatchkine,et al. Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. , 1981, The Journal of clinical investigation.